Niagen Bioscience (NAGE) EBIT (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of EBIT data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, EBIT fell 66.97% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $13.1 million, a 1.1% decrease from a year earlier, with the FY2025 full-year figure at $16.3 million, up 110.7% from the prior year.
• EBIT for Q1 2026 stood at $1.6 million, down from $4.1 million in the prior quarter.
• Over the last five years, EBIT for NAGE reached as high as $7.1 million in Q4 2024 and fell as low as -$7.7 million in Q1 2022.
• Historically, EBIT has averaged $79647.1 across 5 years, with a median of -$256000.0 in 2024.
• Across the five-year window, EBIT surged 4332.74% in 2024 and slumped 66.97% in 2026, its largest moves.
• Year by year, EBIT stood at -$1.4 million in 2022, then surged by 88.37% to -$168000.0 in 2023, then jumped by 4332.74% to $7.1 million in 2024, then plunged by 42.54% to $4.1 million in 2025, then slumped by 61.43% to $1.6 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $1.6 million in Q1 2026, $4.1 million in Q4 2025, and $4.2 million in Q3 2025.